Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial

Kim Vries; Ruud Wortel; Esther Hoop; Wilma Heemsbergen; FJ Pos; Luca Incrocci

doi:10.1016/j.ijrobp.2019.09.007

Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial

Kim Vries, Ruud Wortel, Esther Hoop, Wilma Heemsbergen, FJ Pos, Luca Incrocci

Radiotherapy

Research output: Contribution to journal › Article › Academic › peer-review

40 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	108-115
Number of pages	8
Journal	International Journal of Radiation Oncology Biology Physics
Volume	106
Issue number	1
DOIs	https://doi.org/10.1016/j.ijrobp.2019.09.007
Publication status	Published - 2020

Research programs

EMC OR-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijrobp.2019.09.007

Cite this

Vries, K., Wortel, R., Hoop, E., Heemsbergen, W., Pos, FJ., & Incrocci, L. (2020). Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. International Journal of Radiation Oncology Biology Physics, 106(1), 108-115. https://doi.org/10.1016/j.ijrobp.2019.09.007

Vries, Kim ; Wortel, Ruud ; Hoop, Esther et al. / Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. In: International Journal of Radiation Oncology Biology Physics. 2020 ; Vol. 106, No. 1. pp. 108-115.

@article{660589236dd7465da6bd7e646377e241,

title = "Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial",

author = "Kim Vries and Ruud Wortel and Esther Hoop and Wilma Heemsbergen and FJ Pos and Luca Incrocci",

year = "2020",

doi = "10.1016/j.ijrobp.2019.09.007",

language = "Undefined/Unknown",

volume = "106",

pages = "108--115",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "1",

}

Vries, K, Wortel, R, Hoop, E , Heemsbergen, W, Pos, FJ & Incrocci, L 2020, 'Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial', International Journal of Radiation Oncology Biology Physics, vol. 106, no. 1, pp. 108-115. https://doi.org/10.1016/j.ijrobp.2019.09.007

Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. / Vries, Kim; Wortel, Ruud; Hoop, Esther et al.
In: International Journal of Radiation Oncology Biology Physics, Vol. 106, No. 1, 2020, p. 108-115.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial

AU - Vries, Kim

AU - Wortel, Ruud

AU - Hoop, Esther

AU - Heemsbergen, Wilma

AU - Pos, FJ

AU - Incrocci, Luca

PY - 2020

Y1 - 2020

U2 - 10.1016/j.ijrobp.2019.09.007

DO - 10.1016/j.ijrobp.2019.09.007

M3 - Article

SN - 0360-3016

VL - 106

SP - 108

EP - 115

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 1

ER -

Vries K, Wortel R, Hoop E , Heemsbergen W, Pos FJ, Incrocci L. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial. International Journal of Radiation Oncology Biology Physics. 2020;106(1):108-115. doi: 10.1016/j.ijrobp.2019.09.007